This page shows the latest Mayzent news and features for those working in and with pharma, biotech and healthcare.
Mayzent then received approval from the European Commission (EC) earlier this year, again for the treatment of adults with active SPMS. ... According to NICE, around 11, 000 people with SPMS will now be eligible to receive Mayzent treatment.
Kesimpta’s approval in relapsing MS builds on Novartis’ existing presence in the therapy area, which includes its active secondary progressive multiple sclerosis (SPMS) therapy Mayzent (siponimod).
The drug is an important product in Novartis’ growing MS franchise, which currently includes Mayzent (siponimod), a next-generation treatment approved for use in active secondary progressive multiple sclerosis (SPMS).
If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only
language. Although the patent dispute is an overwhelming win, Biogen has been facing other challenges in the MS market from new treatments, including Novartis’ newly-approved Mayzent and Roche’s Ocrevus.
Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and
More from news
Approximately 5 fully matching, plus 20 partially matching documents found.
4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...